Bromazolam Pellets 3mg compressed triazolobenzodiazepine research material
Bromazolam Pellets - 3mg Price range: € 17,25 through € 725,00
Back to products
Bromonordiazepam Pellets 2.5mg compressed benzodiazepine research pellets
Bromonordiazepam Pellets - 2.5mg Price range: € 15,00 through € 310,00

Bromazolam Blister – 10x 2.5mg

Price range: € 25,90 through € 198,75

Bromazolam Blister 10x 2.5mg is described as a ten-unit blister presentation of bromazolam research tablets, each carrying a nominal 2.5 mg label claim.

The stated total nominal bromazolam content is 25 mg per blister.

Bromazolam is a brominated triazolobenzodiazepine structurally related to alprazolam. The supplied chemical specifications list the molecular formula C17H13BrN4 and molecular weight 353.22 g/mol.

The source reports ingredient purity of at least 98% by HPLC, along with batch traceability, third-party testing, and tablet-content uniformity.

These claims have not been independently verified.

The supplied CAS number, 71368-21-9, differs from the CAS number given in the previous bromazolam pellet brief. The discrepancy requires resolution.

No finished-tablet assay, content-uniformity dataset, or batch-specific Certificate of Analysis was supplied.

Bromazolam is associated with serious benzodiazepine-related hazards, including sedation, dependence, memory impairment, and potentially dangerous interactions with other central nervous system depressants.

For research use only. Not for human or veterinary use. Not for clinical, diagnostic, or consumptive applications.

SKU: CERT-P-12450 Category:
Description

Bromazolam Blister 10x 2.5mg – Research Material Information

Bromazolam Blister 10x 2.5mg – Product Overview

The supplied product is described as a blister-packed presentation containing ten bromazolam research tablets.

Each tablet carries a nominal label claim of 2.5 mg, producing a total nominal pack content of 25 mg.

The source identifies the material as intended for analytical laboratory contexts involving chemical identification, structural characterization, and forensic research.

No finished-tablet assay or independent content-uniformity report was provided.

The stated tablet strength therefore remains a nominal specification rather than a verified batch measurement.

Chemical Identity & Classification

Bromazolam belongs to the triazolobenzodiazepine chemical class and is structurally related to alprazolam.

The supplied specifications are:

  • Compound: Bromazolam
  • Reported synonym: 8-Bromo-1-methyl-6-phenyl-4H-benzo[f]triazolo[4,3-a]diazepine
  • Reported CAS number: 71368-21-9
  • Molecular formula: C17H13BrN4
  • Molecular weight: Approximately 353.22 g/mol
  • Presentation: Ten blister-packed tablets
  • Nominal tablet content: 2.5 mg
  • Total nominal blister content: 25 mg

The supplied formula and molecular weight are internally consistent.

However, the reported CAS number differs from the 71368-80-4 assignment supplied for the bromazolam pellet presentation.

This discrepancy requires verification against authoritative chemical records and batch-specific identity evidence.

Public chemical-reference information can be reviewed through PubChem.

Chemical & Physical Characteristics

The source describes ten individual tablets contained in a blister presentation.

No verified tablet dimensions, color specifications, excipient composition, hardness measurements, or disintegration data were supplied.

The source refers to dissolution characteristics, solubility in ethanol and DMSO, and stability under analytical conditions.

These properties may depend on the chemical form and finished-tablet formulation.

No measured solubility profile or validated dissolution dataset was provided.

The reported melting-point range of approximately 160–162°C has not been independently verified.

Blister packaging alone does not establish tablet-content uniformity or long-term stability.

Purity & Analytical Verification

The source reports a typical ingredient purity of at least 98% by HPLC.

It also claims chemical identity confirmation using HPLC, mass spectrometry, and NMR spectroscopy.

No chromatograms, spectra, impurity profiles, or batch-specific Certificate of Analysis were supplied.

The reported purity remains unverified.

Ingredient purity and finished-tablet content are separate measurements.

A high-purity starting material does not establish that each tablet contains exactly 2.5 mg of bromazolam.

The source describes LC-MS/MS, HPLC/UV, and forensic analytical contexts.

No validated method-performance results or certified reference values were supplied.

Quality Control & Batch Integrity

The brief claims batch traceability, third-party testing, content-uniformity assessment, residual-solvent analysis, and dissolution-profile verification.

It also reports tablet-performance consistency within ±2% relative standard deviation.

No supporting test results were supplied.

The claimed ±2% RSD requires a defined measured parameter, analytical method, sample size, and dataset before it can be interpreted meaningfully.

The source does not establish whether this figure refers to tablet mass, ingredient content, dissolution, or another characteristic.

The reported testing and quality-control statements should therefore be treated as unverified supplier claims.

Safety, Handling & Laboratory Precautions

Bromazolam is a benzodiazepine-related central nervous system depressant.

Potential hazards include sedation, impaired coordination, memory impairment, dependence, withdrawal complications, and respiratory depression.

Concurrent exposure to opioids, alcohol, or other central nervous system depressants can increase the risk of severe harm.

Institutional procedures should address restricted access, suitable protective equipment, contamination prevention, secure inventory control, accidental-exposure response, and waste management.

No verified product-specific Safety Data Sheet was supplied.

The blister presentation does not establish suitability for human or veterinary administration.

Packaging, Labeling & Storage

The source describes ten tablets in tamper-evident blister packaging.

It recommends storage at approximately 2–8°C, protected from light and moisture.

No validated stability study was provided to establish this temperature range as a product-specific requirement.

No verified blister-barrier performance, shelf life, or finished-product stability dataset was supplied.

Tamper-evident packaging should not be equated with certified analytical integrity.

Product labels should distinguish nominal tablet content from batch-verified measurements.

Intended Research Use & Market Positioning

The source identifies analytical laboratory contexts involving triazolobenzodiazepine characterization, chromatographic profiling, and forensic chemical identification.

No certified reference-material status or validated quantitative calibration performance has been established.

The supplied Raw Lab Chems catalog references are:

These references concern norflurazepam, a different benzodiazepine-related compound.

They should not be presented as chemically equivalent bromazolam formulations.

Ordering, Availability & Fulfillment

The source claims international shipping, tracking, customs documentation, protective packaging, and compliance with IATA and DOT requirements.

No current inventory record, transport classification, carrier authorization, or supporting shipment documentation was provided.

These claims cannot be independently confirmed.

Blister packaging does not itself establish IATA or DOT compliance.

Research-only labeling does not automatically exempt a chemical from controlled-substance legislation, analogue laws, or import restrictions.

Transport eligibility and legal authorization depend on the applicable jurisdiction and transaction.

Legal & Regulatory Disclaimer

For research use only. Not for human or veterinary use. Not for clinical, diagnostic, or consumptive applications.

Bromazolam is a psychoactive benzodiazepine-related compound that may be subject to controlled-substance, analogue, chemical-safety, import, and export restrictions.

Institutions are responsible for verifying applicable laws, maintaining necessary authorization, and implementing appropriate laboratory safety and secure custody.

No therapeutic approval, consumer-use authorization, or certified reference-material status is implied.

Additional information
Quantity

2

,

5

,

10

,

25

Reviews (0)

Reviews

There are no reviews yet.

Be the first to review “Bromazolam Blister – 10x 2.5mg”
Shipping & Delivery